Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Ivacaftor Safety in Cystic Fibrosis with Non-G551D CFTR Mutations
2012-000389-39Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Safety. Started Apr 2012; status: completed.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2012-000389-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000389-39.